Conseil d’administration

Nesrin Shaheen

Conseil d’administration

Madame Shaheen est une administratrice et membre fondatrice de la Fondation de l’encéphalite à anticorps antirécepteurs nmda. Sa fille a été le premier cas identifié avec certitude au Canada en janvier 2008. Depuis, sa fille a fait quatre rechutes et continue sa lutte en vue de son rétablissement. Madame Shaheen agit à titre de porte-parole, soutien aux personnes soignantes/patients au sein de la Fondation. Elle détient un baccalauréat ès arts en littérature allemande et langues de l’université McGill ainsi qu’un certificat en édition décerné par The Robert Gordon University, Aberdeen (Écosse). Madame Shaheen travaille au ministère des Affaires étrangères, du Commerce et du Développement, Canada depuis 1991. Elle parle couramment l’anglais, le français et l’allemand.

Gregory Day, M.D.

Conseil d’administration

Dr Day est un neurologue qui a étudié à Toronto. Il achève ses études postdoctorales en recherche clinique à Washington University à St. Louis (Missouri). Ses travaux de recherche portent sur la caractérisation du tableau clinique, la compréhension des processus pathogéniques et l’amélioration des traitements pour les patients atteints de l’encéphalite à anticorps antirécepteurs nmda et de maladies connexes. Dr Day est un administrateur et un membre fondateur de la Fondation de l’encéphalite à anticorps antirécepteurs nmda et il siège à titre de directeur des services cliniques.

Harry E. Peery, M.D.

Conseil d’administration

Dr Peery détient une maîtrise en microbiologie (Ohio State University) et un Ph.D. en pharmacologie (université de la Saskatchewan). Il poursuit actuellement ses études postdoctorales à l’université de Calgary. En plus de ses études, ses intérêts en matière de recherche sont la pathogénie immunologique de l’encéphalite à anticorps antirécepteurs nmda et des autres troubles neuroauto-immun et la détection de tumeurs immunohistochimiques. Dr Perry est un administrateur et un membre fondateur de la Fondation de l’encéphalite à anticorps antirécepteurs nmda et il siège à titre de directeur de recherche.

Yanet Valdez, MSc, PhD

Conseil d’administration

Born in Perú Dr Valdez began her research under Dr Gilman’s supervision (John’s Hopkins and Universidad Peruana Cayetano Heredia, Peru), Dr Valdez led a research team investigating the molecular epidemiology of Helicobacter pylori, a bacterium known as inducer of gastric ulcers and cancer

She then completed her MSc with Dr Townsend at the Biomedical Research Centre at UBC in Vancouver studying fundamental question on how T and B cells communicate to produce an effective immune response.

She did her doctoral studies in Dr Finlay’s lab and revealed novel concepts of innate responses to the pathogen Salmonella, with important implications for human infectious diseases, infectious colitis, IBD and intestinal fibrosis.

After 5 years of post-doctoral work in many institutes in UBC she joined StemCell Technologies Inc. leading a team in Innate Immunology.

She returned to academia and managed the Research Office at the UBC Faculty of Medicine.
Currently, she is an invited lecturer in many Universities in South America

She volunteers for Immunology Without Borders, chapter of the International Union of Immunological Societies, Covid19 Resources Canada, BC Lead, Founder of @ImmunoLatinXs. She is a champion of Equity,Diversity, Inclusion and Women in STEM initiatives in Canada/Globally, and as Board of Directors of the Anti NMDRA Encephalitis Foundation

She is proud mother of two.

Kelly M. McNagny, PhD

Conseil d’administration

Research Specialty: Immunology, Inflammation, Hematology, Cancer Therapeutics

Dr. Kelly McNagny is a full professor in Medical Genetics at The Biomedical Research Centre where his work focuses on stem cell behavior, innate immune responses, inflammatory disease, cancer biology and therapeutics. He is an expert on animal models of human disease and has experience with neuro-inflammatory disease models in mice. Kelly obtained his Ph.D. in Cellular Immunology at the U. of Alabama at Birmingham in 1990. There he worked with Dr. Max D. Cooper (Howard Hughes Medical Institute, National Academy of Sciences) and his research focused on cell surface proteins that regulate B cell maturation and homing. He then moved to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany where he performed his postdoctoral studies in the lab of Dr. Thomas Graf from 1991 to 1996. There his work focused on transcriptional control of hematopoietic stem cell maturation and cell fate. In addition, he identified a number of novel hematopoietic stem cell surface proteins (the CD34 family) and began analyzing their function. He continued his studies at the EMBL as a semi-independent, Visiting Scientist from 1996 to 1998 prior to starting his own laboratory at The Biomedical Research Centre, at UBC. In 2015 he also served as the Scientific Director of the Centre for Drug Research and Development (CDRD), a National Centre of Excellence aimed at translating early stage scientific discoveries into therapies. He has garnered several awards including the 2004 Showell-Pfizer Junior Faculty Award from the American Association for Immunology, a MSFHR Career Investigator Award. Kelly is a member of the Canadian Stem Cell Network Centre of Excellence (Sub-Chair of the Trainee Education Committee), Associate Director of the AllerGen Network Centre of Excellence, and Co-Director of AllerGen’s Biomarkers and Bioinformatics Platform.

Experience: Kelly and his wife are parents of a survivor of Anti-NMDA receptor encephalitis and have first hand experience in the challenges associated with rapidly diagnosing and treating this disease.